FDA Clears Updated AI Software for Lung CT
Reportedly offering improved delineation of pulmonary structures and greater accuracy with computed tomography (CT) values of pulmonary tissue, the artificial intelligence (AI)-powered LungQ 3.0.0. may facilitate enhanced precision and efficiency with interventional procedures such as lung volume reduction and ablation procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for LungQ 3.0.0., an updated version of an artificial intelligence (AI)-enabled software platform for lung computed tomography (CT) scans, which is currently being utilized in more than 600 hospitals.
The enhanced software provides improved visualization and assessment of a variety of structures including lobes, subsegments and the most peripheral locations in the lungs to facilitate diagnosis and appropriate treatment of conditions such as emphysema and COVID-19, according to Thirona, the developer of LungQ 3.0.0.
The LungQ 3.0.0. software platform provides improved visualization and assessment of a variety of lung structures to facilitate improved outcomes with interventional lung procedures in addition to diagnosis and appropriate management of conditions such as emphysema and COVID-19, according to Thirona, the developer of the software.
Noting that the LungQ software platform has been validated in more than 200 publications globally, Thirona said the LungQ 3.0.0. software enhances the precision and efficiency of interventional procedures ranging from lung segmentectomy and ablation procedures to lung cancer biopsies and lung volume reduction.
“A clearer understanding of lung anatomy helps enable broader adoption of minimally invasive treatments for lung diseases such as COPD and lung cancer, helping save more healthy lung tissue and lung function capacity. … Solutions like LungQ are helping usher in a new era of personalized treatment for lung patients, enabling clinicians all over the world to conduct more advanced, easier-to-perform and less invasive procedures with full confidence,” said Eva van Rikxoort, the founder and CEO of Thirona.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
